Federal prosecutors are planning to charge an Ohio doctor
accused of writing hundreds of opioid prescriptions that lacked
a legitimate medical purpose and accepting kickbacks from
drugmaker Insys Therapeutics Inc, his lawyers said on Friday.
Allergy treatment manufacturer Stallergenes Greer has won
the dismissal of a whistleblower lawsuit accusing the company of
selling unlicensed custom blends of allergenic extracts to
doctors that were then billed to government healthcare programs.
A federal appeals court on Friday agreed to reconsider a
ruling that would allow customers in Pennsylvania to hold
Amazon.com Inc liable as the seller of defective products sold
by third-parties through its online marketplace.
A lawsuit by Oklahoma's attorney general accusing Johnson &
Johnson of fueling the opioid epidemic is set to establish a
major precedent over whether a state's public nuisance laws can
be used to hold a drugmaker liable for the U.S. drug crisis.
A federal bankruptcy judge on Thursday instructed Insys
Therapeutics Inc to come up with a new severance program after
creditors demanded assurances that no employees involved in
criminal wrongdoing at the opioid manufacturer would get paid.
A federal appeals court on Thursday ruled a judge misapplied
the law in barring a man who claimed Philip Morris USA's
cigarettes caused his wife's lung cancer death to rely at trial
on facts derived from the U.S. government's own tobacco
An Oklahoma judge will rule on Monday on whether Johnson & Johnson should be held liable in a lawsuit by the state's attorney general who argues the drugmaker should be forced to pay $17 billion for fueling the opioid epidemic.
A requirement that railroad workers file a complaint with
the U.S. Occupational Safety and Health Administration within
180 days of a carrier engaging in whistleblower retaliation is
not a rule that strips courts of jurisdiction over such cases, a
federal appeals court ruled on Wednesday.
A federal judge on Wednesday declined to certify a class of
consumers alleging Shire PLC entered into an improper deal to
delay the release of a generic, cheaper version of the ADHD drug
Intuniv, finding many consumers were uninjured by its actions.
Insys Therapeutics Inc's unsecured creditors and five states
want the drugmaker to ensure no employees "complicit in bad
acts" receive severance after several executives were convicted
of paying doctors bribes to prescribe an opioid medication.